ClinicalTrials.gg
Not yet recruitingNCT07312773Updated Dec 31, 2025

A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C

A Phase 1 interventional study of Treatment A(AD-231A) and Treatment B(AD-231B+AD-231C) in Hypertension and Hyperlipidemia, sponsored by Addpharma Inc.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
19 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 24 studies in Hypertension by Yuhan Corporation — 3 open to participants now, 3 under way, none of them phase 3. Hypertension · Yuhan Corporation.

Planned enrollment
18th of 23
55 · median 80
Started
2026
with 2 others
Phase 1
14 of 24
3 open now
Registered
22nd of 24
by date

Among the 24 studies in Hypertension by Yuhan Corporation, this one is the 18th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2026, is one of 14 in phase 1, and was the 22nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

3 of the 24 studies in Hypertension by Yuhan Corporation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 19 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hypertension by Yuhan Corporation, or all of them as a file.
02

Study summary

To evaluate the pharmacokinetic interactions of AD-231A, AD-231B, and AD-231C in healthy adult volunteers.

03

Conditions studied

  • Hypertension
  • Hyperlipidemia
04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers aged ≥19 and \<65 years at the time of the screening visit
  • Body weight ≥50 kg (≥45 kg for females) and (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study with an drug within the 6 months from scheduled first administration
  • Other exclusions applied
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Arm A

    Period 1 : Treatment A(AD-231A), Period 2 : Treatment C(AD-231A+AD-231B+AD-231C)

    Drug: Treatment A(AD-231A) · Drug: Treatment C(AD-231A+AD-231B+AD-231C)

  • Experimental
    Arm B

    Period 1 : Treatment B(AD-231B+AD-231C), Period 2 : Treatment C(AD-231A+AD-231B+AD-231C)

    Drug: Treatment B(AD-231B+AD-231C) · Drug: Treatment C(AD-231A+AD-231B+AD-231C)

Interventions

  • DrugTreatment A(AD-231A)

    AD-231A Oral Tablet

  • DrugTreatment B(AD-231B+AD-231C)

    AD-231B+AD-231C Oral Tablet

  • DrugTreatment C(AD-231A+AD-231B+AD-231C)

    AD-231A+AD-231B+AD-231C Oral Tablet

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve during dosing interval at steady state (AUCτ,ss)

    AUCτ,ss

    Time frame: pre-dose (0hour) to 24 hours post-dose on Day 14

  2. Maximum concentration of drug in plasma at steady state (Cmax,ss)

    Time frame: pre-dose (0hour) to 24 hours post-dose on Day 14

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Feb 2026, 0 months later.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 0 months is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2025
First posted
Dec 31, 2025
StartEst.
Jan 23, 2026
Primary completionEst.
Feb 7, 2026
CompletionEst.
Feb 22, 2026
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07312773
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Dec 31, 2025
Start date
Jan 23, 2026 (estimated)
Primary completion
Feb 7, 2026 (estimated)
Completion
Feb 22, 2026 (estimated)
Last update
Dec 31, 2025

Study contacts

JaeHun Jung
Contact
jhjung@addpharma.co.kr
+8247679615

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion